News and Events

Statin link with increased NMSC risk

2 February 2016

The use of statins was associated with increased NMSC risk in a cohort of postmenopausal white women, according to an analysis of data from the Women’s Health Initiative (WHI) Observational Study and WHI Clinical Trial. According to the study authors, “as statin use is likely to increase significantly in the future under the new statin use guidelines and NMSC is already the most common cancer in the United States, these results may be important and warrant further investigation”.

New Australian UV, vitamin D and sun protection guidelines

1 February 2016

Cancer Council Australia, along with the Australasian College of Dermatologists, the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia have released new guidelines to ensure consistency of public health advice relating to UV, vitamin D and sun protection.

Sunbeds linked with 6-fold melanoma risk in young women

27 January 2016

Sunbeds were strongly associated with increased melanoma risk among women, especially among women younger than 30 years, according to results of a recent study. For these younger women, indoor tanning was associated with a 6-fold increase in the likelihood of developing melanoma. Furthermore, nearly all women in the study (96.8%) diagnosed as having melanoma when younger than 30 years had engaged in indoor tanning, all initiating indoor tanning before age 25 years, and nearly all (90.5%) engaging in frequent indoor tanning (>10 times per year).

Sunbed focus of European public consultation

25 January 2016

The European Commission and its Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) have launched a public consultation on biological UV effects, with a particular reference to sunbeds.

Pregnancy and melanoma

23 January 2016

Two recently published retrospective studies provide differing perspectives on the influence of pregnancy on the development, progression and prognosis of melanoma.

Melanoma burden by melanoma stage

12 January 2016

Years lived with disability (YLD) generated by localised melanoma which will never metastasise was found to be inferior to years of life lost (YLL) resulting from stage IA melanomas, according to a recent review of the distribution of melanoma burden amongst localised, node metastatic and distant metastatic stages.

MEK inhibitors and their potential in the treatment of advanced melanoma

9 January 2016

In this article the authors provide a review of MEK inhibitors and their potential in the treatment of advanced melanoma, highlighting the need for further research into whether the best strategy to prolong survival is through optimisation of triple therapy or sequential therapy.